Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute Lymphoblastic Leukemia (ALL) Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Complete Remission: Results From the GMALL Study Group.

Matthias Stelljes, MD, Mareike David, Renate Arnold, MD, Dietrich W Beelen, MD, Wolfgang A Bethge, MD, Martin Bornhäuser, MD, Jolanta Dengler, MD, Juergen Finke, MD, Hans J Kolb, MD, Karin Kolbe, MD, Nicolaus Kröger, MD, Dietger Niederwieser, MD, Wolf Rösler, MD, Rainer Schwerdtfeger, MD, Joachim Kienast, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 3352.

https://doi.org/10.1182/blood.V114.22.3352.3352

Published: 2009

Journal Articles

Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Felix Rosenow, Gerda Silling, MD, Berkemeier Almut, MD, Carsten Mueller-Tidow, MD, Steffen Koschmieder, MD, Guido Bisping, MD, Utz Krug, MD, Thomas Buechner, MD, Wolfgang E Berdel, MD, Joachim Kienast, MD, Matthias Stelljes, MD

Blood (2009) 114 (22): 3317.

https://doi.org/10.1182/blood.V114.22.3317.3317

Published: 2009

Journal Articles

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Christoph Schmid, MD, Johanna Tischer, MD, Matthias Stelljes, MD, Michael Schleuning, MD, Rainer Schwerdtfeger, MD, Ute Hegenbart, MD, Joerg Schubert, MD, Wichard Vogel, MD, Berd Gruhn, MD, Christiane Lallinger, Georg Ledderose, MD, Martin Bornhaeuser, MD, Joachim Kienast, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1651.

https://doi.org/10.1182/blood.V110.11.1651.1651

Published: 2007

Journal Articles

Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.

Mattias Stelljes, MD, Joachim Kienast, MD, Björna Berning, MD, Nicola Gokbuget, MD, Dieter Hoelzer, MD, Gerda Silling, MD, Wolfgang E. Berdel, MD, Gary Van Houten Dahl, MD, Debra Schissel, RN, Molly Hemenway, PNP, Lia Gore, MD

Blood (2006) 108 (11): 5340.

https://doi.org/10.1182/blood.V108.11.5340.5340

Published: 2006

Journal Articles

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, MD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria Cristina Sauerland, Dipl Math, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 1977.

https://doi.org/10.1182/blood.V108.11.1977.1977

Published: 2006

Journal Articles

Noninvasive Assessment of Intestinal Graft-Versus-Host Disease Activity by 18F-Fluorodeoxyglucose Positron Emission Tomography.

Matthias Stelljes, MD, Jorn Albring, MD, Sven Hermann, MD, Christopher Poremba, MD, Gabiele Kohler, MD, Christoph Bremer, MD, Thorsten Kucharzik, MD, Gerda Silling, MD, Wolfgang E. Berdel, MD, Otmar Schober, MD, Michael Schafers, MD, Joachim Kienast, MD

Blood (2006) 108 (11): 3230.

https://doi.org/10.1182/blood.V108.11.3230.3230

Published: 2006

Journal Articles

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Matthias Stelljes, MD, Martin Bornhaeuser, MD, Matthias Kroger, MD, Joerg Beyer, MD, Maria C. Sauerland, Achim Heinecke, PhD, Bjorna Berning, MD, Christian Scheffold, MD, Gerda Silling, MD, Thomas Buchner, MD, Andreas Neubauer, MD, Axel Arthur Fauser, MD, Gerhard Ehninger, MD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2006) 108 (11): 3016.

https://doi.org/10.1182/blood.V108.11.3016.3016

Published: 2006

Journal Articles

Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.

Martin Kropff, MD, Guido Bisping, MD, Peter Liebisch, MD, Orhan Sezer, MD, Hermann Einsele, MD, Christian Straka, MD, Nicolaus Kroeger, MD, Bernd Metzner, MD, Monika Engelhardt, MD, Nicola Lang, MD, Marcus Hentrich, MD, Hans Wolf, MD, Christoph von Schilling, MD, Hans Salwender, MD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2005) 106 (11): 2549.

https://doi.org/10.1182/blood.V106.11.2549.2549

Published: 2005

Journal Articles

Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, PhD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria-Cristina Sauerland, Achim Heinecke, PhD, Bernhard Woermann, MD, Wolfgang Hiddemann, MD

Blood (2005) 106 (11): 272.

https://doi.org/10.1182/blood.V106.11.272.272

Published: 2005

Journal Articles

Graft-Versus-Tumor (GvT) Effects in the Absence of Alloantigens on Tumor Cells Crucially Depend on Graft-Versus-Host Disease (GvHD) Intensity.

Jörn C. Albring, MD, Matthias Stelljes, MD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2005) 106 (11): 1304.

https://doi.org/10.1182/blood.V106.11.1304.1304

Published: 2005

Journal Articles

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Guido Bisping, MD, Doris Wenning, Martin H. Kropff, MD, Gerd Munzert, MD, Frank Hilberg, PhD, Gerald J. Roth, PhD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2005) 106 (11): 112.

https://doi.org/10.1182/blood.V106.11.112.112

Published: 2005

Journal Articles

Bortezomib in Combination with Dexamethasone for Relapsed Multiple Myeloma.

Martin H. Kropff, MD, Guido Bisping, MD, Doris Wenning, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2004) 104 (11): 4923.

https://doi.org/10.1182/blood.V104.11.4923.4923

Published: 2004

NARROW

Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Noninvasive Assessment of Intestinal Graft-Versus-Host Disease Activity by 18F-Fluorodeoxyglucose Positron Emission Tomography.

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.

Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML).

Graft-Versus-Tumor (GvT) Effects in the Absence of Alloantigens on Tumor Cells Crucially Depend on Graft-Versus-Host Disease (GvHD) Intensity.

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Bortezomib in Combination with Dexamethasone for Relapsed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only